Cover Image
市場調查報告書

全球視網膜靜脈阻塞市場

Global Retinal Vein Occlusion Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 308874
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
全球視網膜靜脈阻塞市場 Global Retinal Vein Occlusion Market 2014-2018
出版日期: 2014年07月23日 內容資訊: 英文 77 Pages
簡介

視網膜靜脈阻塞,是網膜的血流受阻,眼睛神經細胞損傷也可能導至失明的疾病。由於眼靜脈非常狹窄,可能經由靜脈血栓發生。是患高血壓和糖尿病、血脂異常症的人容易出現的疾病。全球視網膜靜脈阻塞市場,預期今後2013∼2018年以年複合成長率16.04%擴大。

本報告提供全球視網膜靜脈阻塞市場未來的成長預測、市場規模、供應商環境、供應商所面臨的課題與市場發生的主要趨勢等彙整。

第1章 摘要整理

第2章 簡稱

第3章 本報告的範圍

  • 市場概要
  • 產品概要

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 產品研發線

第8章 發病率和罹患率

第9章 各治療市場區隔

  • 生技藥品
  • 皮質類固醇

第10章 各給藥途徑市場區隔

  • 玻璃體內
  • 血管內

第11章 各投藥形態市場區隔

  • 溶液
  • 植入

第12章 各地區市場區隔

第13章 購買標準

第14章 市場成長的促進要素

第15章 促進要素與其影響

第16章 市場課題

第17章 促進要素的影響與課題

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
    • 主要消息
    • 合併、收購
  • 市場佔有率分析
  • 其他值得注意的供應商

第21章 主要供應商分析

  • Bayer
  • Roche
  • Novartis
  • Regeneron Pharmaceuticals

第22章 本系列其他報告

圖表

目錄
Product Code: IRTNTR3864

About Retinal Vein Occlusion

Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

TechNavio's analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.

TechNavio's report, the Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alimera Sciences
  • Bristol-Myers Squibb
  • NicOx
  • Santen Pharmaceutical Co.
  • Valeant Pharmaceuticals International

Key Market Driver

  • High Unmet Need

For a full, detailed list, view our report.

Key Market Challenge

  • Serious Adverse Side Effects

For a full, detailed list, view our report.

Key Market Trend

  • Introduction of Biologics

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Portfolio

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Pipeline Portfolio

08. Rate of Incidence and Prevalence

09. Market Segmentation by Type of Therapy

  • 09.1.1. Biologics
  • 09.1.2. Corticosteroids

10. Market Segmentation by Route of Administration

  • 10.1.1. Intravitreal
  • 10.1.2. Intravenous

11. Market Segmentation by Dosage Forms

  • 11.1.1. Solutions
  • 11.1.2. Implant

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
    • 20.2.1. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Bayer
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation
    • 21.1.4. Business Segmentation by Revenue 2012 and 2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Information
    • 21.1.8. SWOT Analysis
    • 21.1.9. Strengths
    • 21.1.10. Weaknesses
    • 21.1.11. Opportunities
    • 21.1.12. Threats
  • 21.2. Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
    • 21.2.9. Strengths
    • 21.2.10. Weaknesses
    • 21.2.11. Opportunities
    • 21.2.12. Threats
  • 21.3. Novartis
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis
    • 21.3.9. Strengths
    • 21.3.10. Weaknesses
    • 21.3.11. Opportunities
    • 21.3.12. Threats
  • 21.4. Regeneron Pharmaceuticals
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Product Segmentation
    • 21.4.4. Revenue Product Segmentation
    • 21.4.5. Business Strategy
    • 21.4.6. Key Information
    • 21.4.7. SWOT Analysis
    • 21.4.8. Strengths
    • 21.4.9. Weaknesses
    • 21.4.10. Opportunities
    • 21.4.11. Threats

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Retinal Vein Occlusion Market 2013-2018 (US$ million)
  • Exhibit 3: Pipeline Portfolio of the Drugs for the Treatment of Retinal Vein Occlusion
  • Exhibit 4: Global Retinal Vein Occlusion Market by Type of Therapy
  • Exhibit 5: Global Retinal Vein Occlusion Market by Route of Administration
  • Exhibit 6: Global Retinal Vein Occlusion Market by Dosage Forms
  • Exhibit 7: Global Retinal Vein Occlusion Market by Geographical Segmentation
  • Exhibit 8: Global Retinal Vein Occlusion Market Share Analysis 2013
  • Exhibit 9: Product-wise Revenue Share in Global Retinal Vein Occlusion Market 2013
  • Exhibit 10: Bayer AG: Business Segmentation 2013
  • Exhibit 11: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 12: Bayer AG: Sales by Geography 2013
  • Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 17: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 18: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Novartis AG: Sales by Geography 2013
  • Exhibit 20: Regeneron Pharmaceuticals Inc.: Product Segmentation
  • Exhibit 21: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
Back to Top